You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, July 2018
|
| DOI | 10.1186/s13058-018-0970-6 |
| Pubmed ID | |
| Authors |
Aya Asano, Shigeto Ueda, Ichiei Kuji, Tomohiko Yamane, Hideki Takeuchi, Eiko Hirokawa, Ikuko Sugitani, Hiroko Shimada, Takahiro Hasebe, Akihiko Osaki, Toshiaki Saeki |
| Abstract |
Hypoxia is a key driver of cancer progression. We evaluated the prognostic impact of 18F-fluoromisonidazole (FMISO) prior to treatment in patients with breast cancer. Forty-four patients with stage II/III primary breast cancer underwent positron emission tomography/computed with 18F-fluorodeoxyglucose (FDG-PET/CT) and FMISO. After measurement by FDG-PET/CT, the tissue-to-blood ratio (TBR) was obtained using FMISO-PET/CT. FMISO-TBR was compared for correlation with clinicopathological factors, disease-free survival (DFS), and overall survival (OS). Multiplex cytokines were analyzed for the correlation of FMISO-TBR. Tumors with higher nuclear grade and negativities of estrogen receptor (ER) and progesterone receptor had significantly higher FMISO-TBR than other tumors. Kaplan-Meier survival curves showed that patients with a higher FMISO-TBR (cutoff, 1.48) had a poorer prognosis of DFS (p = 0.0007) and OS (p = 0.04) than those with a lower FMISO-TBR. Multivariate analysis indicated that higher FMISO-TBR and ER negativity were independent predictors of shorter DFS (p = 0.01 and 0.03). Higher FMISO-TBR was associated with higher plasma levels of angiogenic hypoxic markers such as vascular endothelial growth factor, transforming growth factor-α, and interleukin 8. FMISO-PET/CT is useful for assessing the prognosis of patients with breast cancer, but it should be stratified by ER status. UMIN Clinical Trials Registry, UMIN000006802 . Registered on 1 December 2011. |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 23% |
| Lecturer | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Student > Bachelor | 2 | 7% |
| Student > Master | 2 | 7% |
| Other | 4 | 13% |
| Unknown | 11 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 27% |
| Physics and Astronomy | 3 | 10% |
| Nursing and Health Professions | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Engineering | 2 | 7% |
| Other | 0 | 0% |
| Unknown | 13 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 July 2018.
All research outputs
#4,838,109
of 25,385,509 outputs
Outputs from Breast Cancer Research
#555
of 2,054 outputs
Outputs of similar age
#86,295
of 341,510 outputs
Outputs of similar age from Breast Cancer Research
#25
of 47 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,510 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.